Table 1.
Bone CT and Biomechanical Results
| Proximal tibia | Femoral mid-diaphysis | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BV/TV (%) |
Cortical Porosity (%) |
Ultimate Force (N) |
Stiffness (N/mm) |
Energy to failure (mJ) |
Ultimate Stress (MPa) |
Modulus (MPa) | Toughness (MJ/m3) |
Cortical thickness(mm) |
Cortical bone area (mm2) |
Cortical porosity (%) |
CSMI (mm4) |
|
| CKD High PTH | ||||||||||||
| CTL | 10.2 ± 1.9 | 2.4 ± 1.7 | 208.9 ± 27.7 | 456.7 ± 64.6 | 93.8 ± 18.5 | 100 ± 16 | 3686 ± 546 | 2.7 ± 0.6 | 0.58 ± 0.10 | 7.4 ± 0.4 | 2.8 ± 2.9 | 22.4 ± 1.8 |
| Scl-Ab | 11.3 ± 3.7 | 7.4 ± 8.5 | 200.5 ± 48.7 | 471.9 ± 99.0 | 83.8 ± 35.4 | 92 ± 28 | 3527 ± 916 | 2.3 ± 1.1 | 0.49 ± 0.19 | 8.1 ± 0.4 | 7.2 ± 5.8 | 23.9 ± 2.2 |
| Zol | 13.0 ± 4.9 | 5.9 ± 6.4 | 211.2 ± 38.3 | 428.8 ± 59.7 | 96.6 ± 30.0 | 104 ± 25 | 3570 ± 683 | 2.8 ± 0.9 | 0.54 ± 0.18 | 7.8 ± 0.6 | 6.2 ± 7.0 | 21.9 ± 2.7 |
| CKD Low PTH | ||||||||||||
| CTL | 21.1 ± 3.6 | 1.3 ± 0.5 | 256.7 ± 20.2 | 561.6 ± 47.5 | 112.6 ± 15.2 | 115 ± 9 | 4306 ± 419 | 2.9 ± 0.5 | 0.80 ± 0.07 | 8.8 ± 0.7 | 4.5 ± 8.3 | 23.6 ± 2.5 |
| Scl-Ab | 25.6 ± 4.3* | 1.5 ± 0.7 | 295.1 ± 27.8 | 593.9 ± 31.1 | 126.6 ± 29.7 | 127 ± 19 | 4224 ± 555 | 3.3 ± 0.9 | 0.80 ± 0.05 | 9.0 ± 0.7 | 0.77 ± 0.48 | 25.7 ± 3.1 |
| Zol | 20.9 ± 3.2 | 1.4 ± 0.7 | 272.3 ± 24.3 | 567.6 ± 43.9 | 111.9 ± 23.5 | 124 ± 11 | 4349 ± 667 | 3.0 ± 0.7 | 0.82 ± 0.06 | 8.9 ± 0.8 | 0.71 ± 0.57 | 23.9 ± 3.7 |
| Normal animals | ||||||||||||
| CTL | 10.2 ± 1.9 | 1.0 ± 0.4 | 268.0 + 21.0 | 562.4 ± 37.5 | 131.1 ± 29.1 | 116 ± 16 | 3767 ± 320 | 3.6 ± 1.0 | 0.73 ± 0.05 | 8.6 ± 0.3 | 1.8 ± 0.6 | 26.4 ± 2.4 |
| Scl-Ab | 16.0 ± 1.9* | 1.2 ± 0.6 | 339.5 ± 31.3+ | 663.5 ± 101.9* | 169.7 ± 29.5* | 114 ± 12 | 3254 ± 443* | 3.9 ± 0.9 | 0.79 ± 0.03 * | 10.3 ± 0.6+ | 1.3 ± 0.3 | 36.8 ± 3.5+ |
CTL= control or no treatment; Scl-Ab = treatment with anti-sclerostin Ab; Zol = treatment with zoledronic acid; CSMI = cross sectional moment of inertia. Data presented as mean and standard deviation.
The CKD animals were compared by two-way ANOVA evaluating the effect of PTH and treatment. There were significant differences (p < 0.01) by PTH group for all bone parameters. There was a significant effect of drug treatment in that treatment with sclerostin Ab was different than control for trabecular bone volume (p = 0.03), cortical bone area (P = 0.05), and CSMI (p = 0.043) with no differences among treatments for the other parameters. Data are mean ± SD.
The Normal animals with and without treatment with anti-sclerostin Ab were compared by t-test.
= p < 0.05,
= p < 0.01.